Message

Message

2019/03/22

Message Ina Research Inc. joined the SNBL (Shin Nippon Biomedical Laboratories) Group in August of 2022, a move that empowered us to offer an even wider range of technologies and services along with enhanced flexibility. With the increase in demand for the latest testing methods and analyses in pharmaceutical development, we have been actively assimilating these rapidly evolving innovative technologies to accommodate the needs of our clients. Regarding our services, we excel at safety studies for advanced technologies such as small molecules, biopharmaceuticals and gene therapies; advanced analytics such as imaging; SEND, our long-held strength; and support for regulatory submission. We conduct nonclinical studies required for the development of test

Published Papers

Published Papers

2019/03/22

Published Papers Papers which Ina Research has published are as follows: Published Papers (2015-) Year Published Paper 2019 Anzai T, Matsuyama T, Wasko M, Hatakeyama H, Horikawa S, Anzai R, Iwata H, Imai N, Mizuhashi F, Tsuboi M, Okuzono T, Takagi H, Cho H, Bryan Tan Siang Rong, Masaki F, and Nakae D. Establishment of the Global SEND Alliance (G-SEND) in Japan and efficient creation of electronic SEND datasets between CROs. J. Toxicol Pathol. Vol.32, 119–126 (2019) 2019 Yamagiwa Y, Takei Y , Koizumi H, Nemoto S, Kurata M, Satoh H. Pathological Features of Corneal Phospholipidosis in Juvenile White Rabbits Induced by Ocular Instillation of Chloroquine or Amiodarone. Toxicol Pathol. Vol.47, 26–34

Agrichemicals

Agrichemicals

2019/03/22

Safety Assessment of Agrichemicals Ina Research Inc. supports a comprehensive range of toxicity tests required in applications for registration of new agricultural chemicals, starting from the screening stage. As a GLP-compliant, AAALAC-accredited* facility, our in vivo/in vitro tests also comply with OECD guidelines and country-specific regulations related to applications and safety assessments for new agricultural chemicals. Upon your request, we also offer consulting services on toxicity evaluation taking into account the regulations of each country.           *Association for Assessment and Accreditation of Laboratory Animal Care International General Toxicity Tests (compliant with OECD Test Guidelines)       Observations, Examinations and Measurements:           ・Clinical observations, body weights, food and water consumption, ophthalmology, urinalysis,            hematology, clinical chemistry, gross pathology,

Chemicals

Chemicals

2019/03/22

Safety Assessment of Chemicals Ina Research conducts safety assessment of chemicals to form the basis for GHS classification, SDS preparation, REACH registration, etc. Our laboratory was the first facility in Japan to be fully-certified by AAALAC International, an international authority on animal welfare. Studies Acute toxicity (oral, dermal)Repeated dose toxicity (subchronic/chronic)In vivo irritation (skin, eyes)In vitro irritation (human skin model, human cornea model)Genotoxicity (Ames test, chromosomal aberration test, micronucleus test)Sensitization (Maximization method, etc.)Reproductive toxicityCarcinogenicity Studies are conducted in compliance with OECD Guidelines.Our experienced researcher will propose appropriate study designs for your goal. Screening Tests We conduct initial screening for acute toxicity, irritation (vivo / vitro) and genotoxicity (Ames), etc. at

Shinanomainichi news posted about new research project for CAR-T cell therapy.

Shinanomainichi news posted about new research project for CAR-T cell therapy.

2018/11/08

Shinshu University establishes a domestic base in Ina toward the practical application of new cancer treatment “CAR-T cell therapy” Shinano Mainichi News as of September 21, 2018 Translated by Ina Research Shinshu University (headquartered in Matsumoto City) will establish a “Gene/Cell Therapy Research and Development Center” (tentative name), a facility for safety studies of “CAR-T cell therapy,” a new immune cell therapy for cancer, at Ina Research Inc. (Ina City) according to a source on September 20. The center will also provide services including safety studies of medical products. The center is planned to become fully operational in fiscal 2019. It was initiated as a government-commissioned project aimed at improving